Breakthrough Technology Alert

This is the best time to be investing in world-changing technologies, as unprecedented innovations are taking off right now...

In Breakthrough Technology Alert, Ray Blanco tirelessly researches these exciting new breakthrough technologies and tells you exactly what you need to do to profit from them.

Orphan Drug Status for NanoViricides One Step Closer to Priority Review Voucher

Unless you're new here, you know about priority review vouchers (PRV). Designed by Duke University economists as a means of encouraging the development of drugs for unaddressed tropical diseases, PRVs were made law in 2007. Essentially, they are transferable go-to-the-front-of-the-regulatory-line “chits” awarded to companies that develop approved drugs for these orphan diseases. Estimates of the financial value of these chits range from $200 million to well over a half billion.

You Must Be A Subscriber To View This Content.

If you are already a subscriber, click the login button below to get access. Not yet a subscriber? Checkout our publication below and get access today!


Breakthrough Technology Alert

This is the best time to be investing in world-changing technologies, as unprecedented innovations are taking off right now… Breakthrough Technology Alert tirelessly researches these exciting new breakthrough technologies to keep you well informed, outline specific opportunities, and keep you ahead of the game.

LoginGet Access

Patrick Cox

Patrick Cox has lived deep inside transformative technologies for over 25 years. In the 1980s, he worked in software development and manufacturing. By the mid-‘90s, he consulted for Netscape–which handled 90% of all Internet browsing traffic at the time. InfoWorld and USA Today have featured his research, and he’s written for The Wall Street Journal,...

View More By Patrick Cox